Company is located in the great State of California;
Aradigm Corporation: Focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases. The Company’s principal activities to date have included conducting research and development and developing collaborations. Management does not anticipate receiving any revenues from the sale of products in the upcoming year, except for royalty revenue from Zogenix, Inc.
@ 16 Cents:, (0.00), (2.50%), $$MM, Some Rounding;
Sum Trading At: ,Primary Metric(s) per CF, (1.82_49) ,Weighted per Price Range / Change, 424.52 ,Primary Weight Adj Trade Metric, (3.98) , (4.84_45) off adjusted level price of 4.9020;
Bottom Line Cash / Current Assets Change Since ’96: Approx +7.4M;
Sum Trading At: ,Primary Metric(s) per CF, 0.01674 ,Weighted per Price Range / Change, 426.3 ,Primary Weight Adj Trade Metric, (41) , (4.84_45) off adjusted level price of 4.9020;(10.731M Market Cap) per Current Shares @ 2.220M;
Net$$M :(-) (133.433) Non Cash Adjustments:(+) 120.170 MinRetGrowth: 0.04 MinRetInv: 0.04 Weighted Cost of Capital: 1.002 Estimated Local Continuing Value in $$M: (3) Estimated Factor NOT LOCAL in $$M: 7 Estimated ContinuingValue:Desired Avg R&D $$M: (19.736,975) Est NOT LOCAL Price on LT Fwd Value : 0.1205_404 (9), Factor Forward. (0.0135), Price To. 0.06% , Desired Percentage Increase in Operating R&D from most recent report. Excludes FV Derivative Adjustments;
The Late Net Phase Bubble Burst Price, The approximate 200K-300K / Share; hahaha!!! [As in, something ridiculous like that,but effective.]
1 Yr % Change (TTM); (99.98%), 10-Day Avg Volume, 1.7M, Large Block Institutional Owners, 7, Total Number of Shares Held 1.2M; [Low Turnover]
Additional Reference that I like to check: Per the USDA Website: Select Beef Cuts; Fat Limitations 1-6; For the Week Ending Today: per 100 lbs; Cut 175, 3 Loin; Strip Loin, 1x1; # of Trades:29, Total Pounds: 321,864; Per 40K LB Loads:8.05; Price Range 424.75 to 457.11; Weighted Average Price 436.15;
Do not own shares; New to Database Recently; Follow the Company;
Note6. Collaborations and Royalty Agreements: Zogenix
In August 2006, the Company sold all of its assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a privately-held pharmaceutical company. Zogenix is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DosePro). Under the terms of the asset sale agreement, the Company received a $4.0 million initial payment from Zogenix and was entitled to a $4.0 million milestone payment upon initial U.S. commercialization, as well as quarterly royalty payments in the amount of 3% of Net Sales of DosePro products. In December 2007, Zogenix submitted a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for the migraine drug sumatriptan using the needle-free injector DosePro (“SUMAVEL* DosePro”). The NDA was accepted for filing by the FDA in March 2008. The same month, Zogenix entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH to develop and commercialize SUMAVEL DosePro in the European Union.